Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06266819
Other study ID # OU-HEM-LE-01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 15, 2024
Est. completion date July 1, 2024

Study information

Verified date February 2024
Source T.C. ORDU ÜNIVERSITESI
Contact leyla emirik
Phone +90 5062848323
Email leylayaguz@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In the research planned as a randomized controlled study, the experimental groups will be administered routine hyperemesis gravidarum (HG) treatment as well as chewing mint-flavored gum, while the control group will only receive routine HG treatment and no intervention will be performed. This study aims to contribute to the literature by investigating the effect of chewing mint-flavored gum on the severity of nausea and vomiting, coping with stress, and anxiety levels due to hyperemesis gravidarum in pregnant women.


Description:

The data of the research will be collected after the necessary institutional permission and ethics committee approval have been obtained. Women who meet the inclusion criteria for the study will be informed about the method to be followed in the research. Those who want to participate in the research will read and sign the volunteer information form. 1. Intervention Group In data collection, pregnant women will sign an informed consent form before the application. Personal Information Form, VAS Scale, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale will be filled out. In addition to the routine treatment plan, the application will begin at least 4 hours after the antiemetic application (Gökbulut, 2021). The application will continue by chewing mint-flavored gum twice a day for at least 15 minutes for 3 days. The VAS scale will be filled after the morning chewing application, and the VAS Scale, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale will be filled in after the evening application. The forms of patients discharged during this period will be filled in via phone. 2. Control Group In data collection, pregnant women will sign an informed consent form before the application. At least 4 hours after the antiemetic application (Gökbulut, 2021), the Personal Information Form, VAS Scale, PUQE Scale and Stress Coping Styles Scale and State Anxiety Scale will be filled out. Routine treatment and nursing care will be applied to the control group, and no intervention will be performed. 1. After the forms are applied, the forms will continue to be filled for 3 days: VAS Scale in the morning, VAS Scale in the evening, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale. The forms of discharged patients will be filled in via phone.


Recruitment information / eligibility

Status Recruiting
Enrollment 78
Est. completion date July 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Pregnant women aged 18 and over - At least primary school graduate - The one who is married - Pregnant women who are younger than 16 weeks of gestation and diagnosed with hyperemesis - Those who agreed to participate in the study Exclusion Criteria: - Those with a history of chronic disease - Having a health problem that may cause nausea and vomiting in the current pregnancy - Those who are allergic to mint

Study Design


Related Conditions & MeSH terms


Intervention

Other:
chewing gum
In addition to the routine treatment plan, mint-flavored gum will be chewed for an average of 15 minutes at least 4 hours after the antiemetic application.

Locations

Country Name City State
Turkey Özel Sar Hospital Rize

Sponsors (1)

Lead Sponsor Collaborator
T.C. ORDU ÜNIVERSITESI

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pregnancy-Specific Nausea and Vomiting Severity Scale (PUQE-24) It was developed to evaluate the severity of pregnancy-specific nausea and vomiting in the last 24 hours. Pregnancy-Specific Nausea and Vomiting Severity Scale (PUQE-24) consists of 3 questions: "duration of nausea or stomach discomfort", "number of vomiting" and "number of retching". Answers to the questions are scored between 1-5 points. The total score of the scale is obtained by the sum of the scores of the answers given to the questions. The lowest score that can be obtained from the scale is 3 and the highest score is 15. If the total score obtained as a result of the PUQE-24 scoring system is 3-6, it is considered mild, 7-12 is considered moderate, and 13-15 is considered severe nausea and vomiting. The scale has no subdimensions. Cronbach's alpha value of the Turkish version of the scale is 0.75. 8 hours
Primary Visual Analog Scale (VAS) It is used for pain assessment in musculoskeletal and other clinical evaluations. VAS is used to convert some values that cannot be measured numerically into numerical values. It is a frequently used measurement tool because it is easy to apply and safe. At the left end of the 10 cm long horizontal line are the words 'I have no pain' and at the right end the words 'I have pain'. The individual is told to mark the point on this horizontal line that best expresses the intensity of pain in his body. The distance of the point marked by the individual to the left end is measured and the pain score is determined. As the VAS value approaches 10, the intensity of the pain increases, and as it approaches 0, the intensity decreases. The lowest score from the scale is 0 and the highest score is 10. 8 hours
Secondary Stress Coping Styles Scale (SCSS) Coping with Stress Coping Styles Scale is a four-point Likert type, consisting of 30 items and 5 subscales. Effective coping styles with stress are evaluated with the "Self-Confident Approach", "Optimistic Approach" and "Social Support Seeking Approach" sub-dimensions, while ineffective coping styles in coping with stress are evaluated with the "Helpless Approach" and "Submissive Approach" sub-dimensions. Higher scores indicate that the person uses more stress coping style. Cronbach Alpha Coefficients of the scale were found to be 0.78 for "Optimistic Approach", 0.83 for "Self-Security Approach", 0.90 for "Helpless Approach", 0.89 for "Submissive Approach" and 0.61 for "Seeking Social Support". 8 hours
Secondary State-Trait Anxiety Inventory (STAI) State-Trait Anxiety Inventory (STAI) determines how an individual feels at a certain moment and condition. STAI consists of 20 items and answers are answered according to the degree of intensity of emotions or behaviors as (1) not at all, (2) a little, (3) a lot, (4) completely. Items 1, 2, 5, 8, 10, 11, 15, 16, 19 and 20 in the scale are reverse scored. The STAI score is calculated by adding 50 points to the difference between the total weighted scores of direct statements and reverse statements. Scores between 20 and 80 can be obtained from STAI. If the score is below 36, it is considered that there is no anxiety, between 37 and 42 points, there is mild anxiety, and those with a score of 42 and above are considered to have high anxiety. 8 hours
See also
  Status Clinical Trial Phase
Completed NCT04785911 - Use of the Modified PUQE Score on Admitted Cases of Hyperemesis Gravidarum (HG) to Guide Response to Treatment
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Completed NCT04719286 - MinSafeStart - Decision Aid Tool for Better Treatment of Nausea and Vomiting During Pregnancy N/A
Completed NCT02300155 - Improving Multivitamin Supplementation to Pregnant Women Phase 4
Completed NCT05175079 - Acupressure in Hyperemesis Gravidarum N/A
Completed NCT05098067 - Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy Phase 2
Completed NCT01836835 - Pregnancy Specific Nausea Questionnaire (PUQE) Translated and Tested in Norwegian N/A
Completed NCT03950167 - Gallbladder Functions & Serum Cholecystokinin Levels in Women Diagnosed With Hyperemesis Gravidarum
Completed NCT02830321 - The Association of Helicobacter Pylori in the Pathogenesis of Hyperemesis Gravidarum in Pregnant Women N/A
Completed NCT02541682 - Assessment of the Relationship Between Affective Temperament and the Severity of Nausea and Vomiting in Early Pregnancy N/A
Terminated NCT03785691 - Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum Phase 2
Completed NCT05446025 - The Levels of the Orexin, Galanin and aMSH and CART in Patients With Hyperemesis Gravidarum
Recruiting NCT02862496 - Bone Health in Hyperemesis Gravidarum N/A
Completed NCT02163434 - Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum Phase 2
Terminated NCT05452174 - Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP) Phase 1/Phase 2
Not yet recruiting NCT06442813 - Effects Of Emotional Freedom Technique and Hypermesis Gravidarum N/A
Completed NCT06245811 - Inflammation Markers in Hyperemesis Gravidarum
Completed NCT04828967 - Use of Hypnosis in Hyperemesis Gravidarum N/A
Completed NCT03127293 - Hyperemesis Gravidarum and Osteoporosis N/A
Completed NCT01559012 - Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum Phase 3